Despite decades of research and control efforts, brucellosis remains a significant global health concern, posing a threat to both animal and human populations. As a renowned research service provider, our company provides one-stop brucellosis vaccine and therapy development services to global pharmaceutical companies.
Introduction to Brucellosis
Brucellosis is a highly contagious zoonotic disease caused by Brucella bacteria, which primarily affects livestock such as cattle, sheep, goats, and pigs. The disease is characterized by a range of nonspecific symptoms, including fever, fatigue, and joint/muscle pain, making it difficult to diagnose and often leading to chronic, debilitating conditions.
The Brucella bacteria are particularly adept at evading the host's immune system, allowing them to establish persistent intracellular infections. This "stealth mode" of operation enables the bacteria to proliferate and disseminate within the host, contributing to the chronic and relapsing nature of brucellosis.
Fig. 1 Timeline of introduction of blood culture methods for isolation of Brucella organisms. (Yagupsky P., et al., 2019)
Vaccine Development for Brucellosis
The search for an ideal brucellosis vaccine has been an ongoing pursuit, as currently available options exhibit various drawbacks. The widely used Brucella abortus S19 and Brucella melitensis Rev.1 vaccines, while providing good protection, suffer from issues such as residual virulence, interference with serodiagnostic tests, and safety concerns for human use. Another vaccine, Brucella abortus RB51, has shown variable efficacy and resistance to important antibiotics used to treat the disease. To address these limitations, researchers have explored innovative approaches to vaccine development.
Table 1 Summary of Brucella vaccine and their properties. (Lalsiamthara J., et al., 2017)
| Vaccine |
General properties and remarks |
| Live |
1)S19,Rev.1: high levels of protection;residual virulence;zero interference;reports of human infections; not suitable for human use; severe local reactions in actively infected individuals
2) RB51, Knock-out; differentiating infected from vaccinated animals (DIVA); comparatively safe; varying level of protection
|
| Inactive cell lysate |
Highly safe; no residual virulence; low level of protection; requires multiple boosters |
| Subunit |
Highly safe; no residual virulence; low level of protection; requires multiple boosters; DIVA; a cross-protecting platform; suitable for human use |
| DNA |
Highly safe; no residual virulence; low level of protection; requires multiple boosters; requires prime boosting; DIVA; a cross-protecting platform. |
| Synthetic peptide |
Highly safe; highly optimizable; no residual virulence; low level of protection; requires multiple boosters; DIVA; a cross-protecting platform; suitable for human use |
| Live vectored |
Safe; customizable; no residual virulence; DIVA; a cross-protectin platform; varying level of protection; suitable for human use |
Therapeutics Development for Brucellosis
One area of focus in brucellosis therapy development is the exploration of novel antimicrobial compounds and drug combinations. Researchers are investigating the potential of various antibiotics, alone or in synergistic combinations, to improve the clearance of Brucella infections, particularly in cases of chronic or drug-resistant disease. The identification of host-directed therapies that can enhance the immune system's capacity to eliminate the intracellular pathogen is another promising avenue.
Additionally, the development of targeted delivery systems, such as nanoparticle-based or liposomal formulations, may improve the bioavailability and targeting of antimicrobial agents to the sites of Brucella infection, potentially enhancing the efficacy of brucellosis therapeutics. Below is our one-stop brucellosis therapy development process. You can click on the link to learn more.
Our Services
At our company, we are committed to advancing the field of brucellosis research and leveraging our expertise to support the development of innovative vaccines and therapies. Our team of experienced scientists and researchers specializes in various aspects of brucellosis research, from an in-depth understanding of Brucella biology to the design and evaluation of novel vaccine and therapeutic candidates.
Infectious Disease Models
- Intraperitoneal Infection Models
- Digestive Route Infection Models
- Nasal (Aerosol) Infection Models
- Reproductive Tract Pathogenesis Models
By leveraging our extensive expertise and state-of-the-art facilities, our company provides customized services as per our clients' needs. If our services have piqued your interest, we warmly welcome you to reach out to us for further information and to obtain a detailed quotation for the services you require.
References
- Yagupsky Pablo, Pilar Morata, and Juan D. Colmenero. "Laboratory diagnosis of human brucellosis." Clinical microbiology reviews 33.1 (2019): 10-1128.
- Lalsiamthara, Jonathan, and John Hwa Lee. "Development and trial of vaccines against Brucella." Journal of Veterinary Science 18.S1 (2017): 281-290.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
